Form: 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

May 28, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549
  
FORM 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of: May 2013
 Commission File Number:  000-54771
 
Acasti Pharma Inc.
(Name of Registrant)
 
545 PROMENADE DU CENTROPOLIS, SUITE 100
LAVAL, QUEBEC, CANADA H7T 0A3
(Address of Principal Executive Offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F [  ]
Form 40-F [X]
                                                
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]
 
 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
 
Acasti Pharma Inc.
     
Date:  May 28, 2013
By:
/s/ Henri Harland
 
Name: 
Henri Harland
 
Title: 
Chief Executive Officer
 
 
 
 
 
 
 

 
EXHIBIT INDEX
 
   
Exhibit
Description of Exhibit
99.1
Notice of Annual and Special Meeting of Shareholders
99.2
Management Proxy Circular
99.3
Notice-And-Access Notification for Annual and Special Meeting of Shareholders
99.4
Form of Proxy